ACSL4 Promotes the Formation of the Proliferative Subtype in Hepatoblastoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Date 2025 Feb 3

PMID 39901207

Authors

Wei Dang

Qin Li

Xiaoying Wang

Affiliations

Soon will be listed here.

Abstract

Hepatoblastoma (HB) is the most common pediatric liver malignancy, with its significant heterogeneity complicating the identification of the most aggressive subtypes and the development of targeted therapies. In this study, we performed transcriptomic analysis of HB samples from the GEO database and identified three distinct molecular subtypes with varying prognostic outcomes. Among them, the proliferative subtype, characterized by enhanced proliferative capacity, poor prognosis, and an immunosuppressive tumor microenvironment, was particularly notable. ACSL4 emerged as a critical biomarker of this proliferative subtype, driving HB cell proliferation both in vitro and in vivo. Furthermore, pharmacological inhibition of ACSL4 using abemaciclib significantly suppressed tumor growth in xenograft models. Mechanistically, ACSL4 was found to promote cell proliferation by downregulating the interferon response signaling pathway which may implicate contribution to immunosuppression in the tumor. These findings underscore the pivotal role of ACSL4 in HB progression and highlight its potential as a therapeutic target for aggressive HB subtypes.

References

Claveria-Cabello A, Herranz J, Latasa M, Arechederra M, Uriarte I, Pineda-Lucena A . Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol. 2023; 79(4):989-1005. DOI: 10.1016/j.jhep.2023.05.031. View

Yang B, Chou J, Tao Y, Wu D, Wu X, Li X . An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer. 2018; 4:35. PMC: 6206135. DOI: 10.1038/s41523-018-0088-0. View

Wang J, Zhu H, You P, Liu H, Wang W, Fan X . Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway. J Clin Invest. 2022; 132(8). PMC: 9012288. DOI: 10.1172/JCI146536. View

Meyers R, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A . Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2016; 18(1):122-131. PMC: 5650231. DOI: 10.1016/S1470-2045(16)30598-8. View

Jin S, Guerrero-Juarez C, Zhang L, Chang I, Ramos R, Kuan C . Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021; 12(1):1088. PMC: 7889871. DOI: 10.1038/s41467-021-21246-9. View

Song H, Bucher S, Rosenberg K, Tsui M, Burhan D, Hoffman D . Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nat Commun. 2022; 13(1):4878. PMC: 9411569. DOI: 10.1038/s41467-022-32473-z. View

Wei D, Rui B, Qingquan F, Chen C, Ping H, Xiaoling S . KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer. Int J Biol Sci. 2021; 17(2):514-526. PMC: 7893577. DOI: 10.7150/ijbs.54074. View

Roehrig A, Hirsch T, Pire A, Morcrette G, Gupta B, Marcaillou C . Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma. Nat Commun. 2024; 15(1):3031. PMC: 11001886. DOI: 10.1038/s41467-024-47280-x. View

Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sabat M, Abril-Fornaguera J . Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol. 2020; 73(2):328-341. DOI: 10.1016/j.jhep.2020.03.025. View

10.

Stockwell B . Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022; 185(14):2401-2421. PMC: 9273022. DOI: 10.1016/j.cell.2022.06.003. View

11.

Wu L, Hong X, Yang C, Yang Y, Li W, Lu L . Noncanonical MAVS signaling restrains dendritic cell-driven antitumor immunity by inhibiting IL-12. Sci Immunol. 2023; 8(90):eadf4919. DOI: 10.1126/sciimmunol.adf4919. View

12.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

13.

Huang H, Wu L, Lu L, Zhang Z, Qiu B, Mo J . Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma. Hepatology. 2022; 77(6):1911-1928. DOI: 10.1002/hep.32775. View

14.

Li Z, Zhang H, Li Q, Feng W, Jia X, Zhou R . GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases. Sci Data. 2023; 10(1):376. PMC: 10257690. DOI: 10.1038/s41597-023-02257-1. View

15.

Mayer-Barber K, Yan B . Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol. 2016; 14(1):22-35. PMC: 5214938. DOI: 10.1038/cmi.2016.25. View

16.

Espinoza A, Patel R, Patel K, Badachhape A, Whitlock R, Srivastava R . A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024; 80(4):610-621. DOI: 10.1016/j.jhep.2024.01.003. View

17.

Duan J, Wang Z, Duan R, Yang C, Zhao R, Feng Q . Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. Hepatology. 2021; 75(1):140-153. PMC: 8688219. DOI: 10.1002/hep.32148. View

18.

Failli M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, Royo L, Domingo-Sabat M . Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response. Hepatology. 2023; 80(1):55-68. PMC: 11185924. DOI: 10.1097/HEP.0000000000000601. View

19.

Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y . CD8 T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022; 40(4):365-378.e6. PMC: 9007863. DOI: 10.1016/j.ccell.2022.02.003. View

20.

Paz S, Vilasco M, Werden S, Arguello M, Joseph-Pillai D, Zhao T . A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cell Res. 2011; 21(6):895-910. PMC: 3203699. DOI: 10.1038/cr.2011.2. View